Olaparib
Stories
-
AstraZeneca posts results of L-MOCA olaparib maintenance trial
The company posted first results for its Phase 3 L-MOCA study, enrolling 225 participants who received olaparib 300mg tablets as maintenance therapy after platinum-based chemotherapy. The trial, which began on May 29, 2018, completed primary data collection on January 27, 2025.